MiMedx Group, Inc.

MiMedx Group, Inc. is a biopharmaceutical company that develops and markets regenerative biomaterial products and bioimplants derived from human placental tissues, including amniotic membrane, birth tissues, human skin, and bone. Headquartered in Marietta, Georgia, the company's mission is to be a leading global provider of healing solutions through continuous innovation to restore quality of life.

MiMedx's product portfolio, processed using its proprietary PURION process, includes allografts such as EpiFix and AmnioFix, which are utilized for both external and internal applications. Other key products include AmnioCord, EpiBurn, EpiCord, EpiXpress, ChorioFix, Emerge, Celera, RegenKit Wound Gel, EpiEffect, AmnioBurn, AmnioEffect, AxioFill, Heliogen, G4Derm Plus, and Hydrelix. These products are primarily targeted at the wound care, burn, surgical, sports medicine, and orthopedics markets, with additional applications in ophthalmic surgery and dental fields.

Joseph H. Capper serves as the Chief Executive Officer, having been appointed in January 2023. In the first quarter of 2026, MiMedx reported a 33% year-over-year decrease in net sales, largely attributed to new Medicare reimbursement policies that significantly impacted the advanced wound care market, leading to a 60% decline in its wound business. Despite these challenges, the surgical business segment demonstrated growth, increasing by 13% year-over-year. The company has initiated a restructuring and cost reduction plan, anticipating $40 million in annualized savings, and projects a return to profitability by the third quarter of 2026, with full-year adjusted EBITDA expected to be approximately breakeven. MiMedx maintains a strong financial position with substantial cash and cash equivalents.

Latest updates

MiMedx Sales Plunge as Reimbursement Changes Rock Wound Care

Event summary

  • MiMedx reported $59 million in net sales for Q1 2026, a 33% decrease from $88 million in Q1 2025.
  • The company's Wound business sales declined 60% year-over-year, while Surgical sales increased 13%.
  • MiMedx is revising its full-year 2026 net sales expectations to a range of $260 to $290 million.
  • The company expects $40 million in annualized cost savings from restructuring efforts, aiming for profitability by year-end.

The big picture

New Medicare reimbursement policies have created significant disruption in the advanced wound care market, impacting MiMedx’s sales and profitability. The company's reliance on Medicare reimbursement, coupled with the inconsistent implementation by MACs, exposes it to regulatory risk. MiMedx’s focus on cost reduction and the relative strength of its Surgical business offer a potential path to recovery, but the company’s future hinges on navigating a challenging market landscape.

What we're watching

Market Adoption
The pace at which wound care providers fully adapt to the new Medicare reimbursement rules will dictate the speed of MiMedx’s revenue recovery and the sustainability of the observed signs of volume recovery.
Competitive Landscape
How MiMedx’s competitors respond to the altered reimbursement environment and the company’s cost-cutting measures will determine whether MiMedx can truly lead the market as management anticipates.
Execution Risk
The ability of MiMedx to achieve its projected $40 million in annualized cost savings and return to profitability will be critical, and hinges on successful implementation of restructuring initiatives.
CID: 1352